Correction

The Difference in Clinical Outcomes Between Osimertinib and Afatinib for First-Line Treatment in Patients with Advanced and Recurrent EGFR-Mutant Non-Small Cell Lung Cancer in Taiwan (vol 17, pg 295, 2022)

TARGETED ONCOLOGY (2023)

Volume 18, Issue 1, Pages 179-180

DOI: 10.1007/s11523-022-00928-4

Click your name to claim this paper and add it to your profile.